Literature DB >> 11836585

Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis.

Sharon Marsh1, Judith A McKay, Stephanie Curran, Graeme I Murray, James Cassidy, Howard L McLeod.   

Abstract

Analysis of tumour markers is helping to predict individual patient response to chemotherapy. However, the difficulties in obtaining metastatic disease samples has led to a reliance on assessment of primary tumour, with little data on its predictive ability. This study assessed thymidylate synthase (TS), a target for the commonly used drug 5FU, in 42 paired primary colorectal tumour and lymph node metastasis. High TS staining was seen in 63% of primary colon tumour cells and 81% of the secondary lymph node. Primary tumour did not have significant predictive power for secondary tumour samples (kappa=0.125; p=0.38). There was no significant relationship between TS staining and expression of G1/S cell cycle proteins p21, p27, p53, cyclin D1, proliferating cell nuclear antigen (PCNA) and retinoblastoma protein (Rb) (p>0.05 in all cases). Discordance in TS protein levels between primary and secondary tumours demonstrates the danger of predicting outcome after chemotherapy in metastatic colorectal cancer from the primary tumour.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836585

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 2.  Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review.

Authors:  Andrea Formentini; Doris Henne-Bruns; Marko Kornmann
Journal:  Langenbecks Arch Surg       Date:  2004-08-12       Impact factor: 3.445

3.  Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes.

Authors:  J P Burke; J H M Prehn; E O'Connell; I S Reynolds; M Salvucci; D A McNamara
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

4.  Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer.

Authors:  Anastasios Ntavatzikos; Aris Spathis; Paul Patapis; Nikolaos Machairas; George Peros; Stefanos Konstantoudakis; Danai Leventakou; Ioannis G Panayiotides; Petros Karakitsos; Anna Koumarianou
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

5.  Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy.

Authors:  Massimo Libra; Patrick M Navolanic; Renato Talamini; Erica Cecchin; Franca Sartor; Salvatore Tumolo; Sara Masier; Salvatore Travali; Mauro Boiocchi; Giuseppe Toffoli
Journal:  BMC Cancer       Date:  2004-03-25       Impact factor: 4.430

6.  Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy.

Authors:  F V Negri; N Campanini; R Camisa; F Pucci; S Bui; G Ceccon; R Martinelli; M Fumagalli; P L Losardo; P Crafa; C Bordi; S Cascinu; A Ardizzoni
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

7.  Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach.

Authors:  So Won Lee; Hyunjin Park; Ho Yun Lee; Insuk Sohn; Seung-Hak Lee; Jun Kang; Jong-Mu Sun; Myung-Ju Ahn
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.